Pfizer Inc. Announces European Medicines Evaluation Agency Acceptance of Regulatory Submission For Tofacitinib For the Treatment of Rheumatoid Arthritis
Published: Nov 21, 2011
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA). Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure.